Page 64 - NPPA full book

Bulk Drugs and Drug Intermediates

The Indian bulk drug industry has also evolved over the me to meet global needs having focused on efficiency, quality, and

technical skill-set and has grown at an annual growth (CAGR) of 6 % from 2004-2005 to 2022-23.

The Indian bulk drug industry has evolved over me to meet global

needs of pharmaceu cal industry. The patent regime during 1970s

brough the generic revolu on in India. Economic liberaliza on policies
introduced in the early 1990s, further opened opportuni es which not

only helped India to be self-sufficient but also expanding global

presence through exports of APIs. From 2000s Indian bulk drug

industry saw massive growth catering to world markets with greater

availability of talent pool, cost advantage and diversified therapeu c
category offerings. During the period, India has grown beyond

manufacturing first-line small molecule APIs to key therapy bulk drugs

involving complex chemistry.

Significant capital inflows in Indian bulk pharma companies over the
past two years has expanded capaci es, made backward integra ons, Dr. Murali. K. Divi, MD

and diversified product offerings. These expansion strategies and Divi’s Laboratories Limited

Government ini a ves like PLI scheme will strengthen India’s pharma

sector, reducing import dependence significantly. Even though there

may s ll be dependency for certain materials, the objec ve in the long run is to build drug-resilient ecosystem. Focus
on manufacturing with sustainability-led opera ng decisions at the core will drive future growth.

Over the past 30 years, Divi’s has become one of the top API manufacturers in the world in terms of revenue with

three major streams of business: Generic APIs, Custom Synthesis and Nutraceu cals. We have achieved the scale in

Generic APIs by focusing on select few products and inves ng on backward integra on for the same years ago

Custom synthesis business demands to be above the standard in all aspects. Today Divi’s works with 12 out of 20 top

innovators and has gained the trust of top MNCs with technical competency, best-in-class safety standards,

capability to handle complex chemistry technologies and focus on green chemistry principles.

Bulk Drug Plant of Hetero Drugs Limited, Hyderabad

54 55